Cardioprotective Effects of Increased Endogenous Erythropoietin After Normobaric Oxygen Breathing

Status:

WITHDRAWN

Cardioprotective Effects of Increased Endogenous Erythropoietin After Normobaric Oxygen Breathing

Lead Sponsor:

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Conditions:

Healthy

Coronary Artery Bypass Graft

Eligibility:

All Genders

18-80 years

Phase:

Brief Summary

Tissue hypoxia is the only accepted trigger for erythropoietin (EPO) production. However, in healthy subjects EPO concentrations have also increased after oxygen breathing. The aim of our study is to ...

Detailed Description

Currently, renal tissue hypoxia is the only widely accepted trigger for erythropoietin (EPO) production. However, previous studies in healthy subjects have demonstrated that a sudden and sustained dec...

Eligibility Criteria

Inclusion

healthy non-smokers; patients undergoing CABG under cardiopulmonary bypass

Exclusion

Subjects with a pulmonary disease; subjects who have stayed at high altitude since at least 3 months; healthy subjects taking medication; patients undergoing a redo or combined cardiac surgery; patients with renal insufficiency; any emergency CABG; Patients with pulmonary disease

Key Trial Info

Start Date :

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT00824759

Last Update

November 19 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)